i-SENS, Inc. (099190.KQ)
KRW 15420.0
(1.65%)
KRW 15420.0
(1.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 10.92 Billion KRW | -48.23% |
| 2022 | 19.14 Billion KRW | -43.39% |
| 2021 | 33.82 Billion KRW | 11.07% |
| 2020 | 30.45 Billion KRW | 4.39% |
| 2019 | 29.17 Billion KRW | 6.47% |
| 2018 | 27.4 Billion KRW | 20.42% |
| 2017 | 22.75 Billion KRW | -11.04% |
| 2016 | 25.58 Billion KRW | 31.77% |
| 2015 | 19.41 Billion KRW | 7.11% |
| 2014 | 18.12 Billion KRW | -2.33% |
| 2013 | 18.55 Billion KRW | 133.83% |
| 2012 | 7.93 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 3.82 Billion KRW | 94.04% |
| 2024 Q1 | 753 Million KRW | -75.21% |
| 2024 Q2 | 1.97 Billion KRW | 161.62% |
| 2023 Q2 | 3.83 Billion KRW | -13.99% |
| 2023 FY | 9.91 Billion KRW | -48.23% |
| 2023 Q1 | 4.46 Billion KRW | 374.61% |
| 2023 Q3 | -448.68 Million KRW | -111.69% |
| 2023 Q4 | 3.03 Billion KRW | 776.96% |
| 2022 Q2 | 7.34 Billion KRW | -25.14% |
| 2022 Q1 | 9.8 Billion KRW | 86.61% |
| 2022 FY | 19.14 Billion KRW | -43.39% |
| 2022 Q4 | -1.62 Billion KRW | -143.94% |
| 2022 Q3 | 3.69 Billion KRW | -49.63% |
| 2021 FY | 33.82 Billion KRW | 11.07% |
| 2021 Q2 | 11.02 Billion KRW | 35.38% |
| 2021 Q3 | 9.38 Billion KRW | -14.83% |
| 2021 Q1 | 8.14 Billion KRW | 45.0% |
| 2021 Q4 | 5.25 Billion KRW | -44.02% |
| 2020 Q3 | 8.83 Billion KRW | 4.85% |
| 2020 FY | 30.45 Billion KRW | 4.39% |
| 2020 Q4 | 5.61 Billion KRW | -36.43% |
| 2020 Q2 | 8.42 Billion KRW | 11.12% |
| 2020 Q1 | 7.58 Billion KRW | 15.59% |
| 2019 FY | 29.17 Billion KRW | 6.47% |
| 2019 Q4 | 6.55 Billion KRW | -20.64% |
| 2019 Q3 | 8.26 Billion KRW | -4.87% |
| 2019 Q2 | 8.68 Billion KRW | 30.47% |
| 2019 Q1 | 6.65 Billion KRW | -32.44% |
| 2018 Q3 | 7.39 Billion KRW | 65.58% |
| 2018 FY | 27.4 Billion KRW | 20.42% |
| 2018 Q2 | 4.46 Billion KRW | -21.57% |
| 2018 Q1 | 5.69 Billion KRW | -8.21% |
| 2018 Q4 | 9.85 Billion KRW | 33.36% |
| 2017 Q2 | 5.84 Billion KRW | 5.2% |
| 2017 FY | 22.75 Billion KRW | -11.04% |
| 2017 Q1 | 5.55 Billion KRW | -14.12% |
| 2017 Q3 | 5.16 Billion KRW | -11.65% |
| 2017 Q4 | 6.2 Billion KRW | 20.14% |
| 2016 FY | 25.58 Billion KRW | 31.77% |
| 2016 Q2 | 6.74 Billion KRW | 23.93% |
| 2016 Q1 | 5.44 Billion KRW | 8.85% |
| 2016 Q3 | 6.92 Billion KRW | 2.75% |
| 2016 Q4 | 6.46 Billion KRW | -6.7% |
| 2015 Q1 | 4.04 Billion KRW | -20.54% |
| 2015 Q4 | 4.99 Billion KRW | -1.2% |
| 2015 Q2 | 5.31 Billion KRW | 31.42% |
| 2015 Q3 | 5.05 Billion KRW | -4.75% |
| 2015 FY | 19.41 Billion KRW | 7.11% |
| 2014 Q3 | 4.89 Billion KRW | 22.7% |
| 2014 FY | 18.12 Billion KRW | -2.33% |
| 2014 Q1 | 4.14 Billion KRW | -21.23% |
| 2014 Q4 | 5.08 Billion KRW | 3.84% |
| 2014 Q2 | 3.99 Billion KRW | -3.74% |
| 2013 Q1 | 3.63 Billion KRW | 36.85% |
| 2013 Q2 | 4.57 Billion KRW | 25.86% |
| 2013 FY | 18.55 Billion KRW | 133.83% |
| 2013 Q3 | 5.08 Billion KRW | 11.15% |
| 2013 Q4 | 5.26 Billion KRW | 3.56% |
| 2012 Q3 | 1.6 Billion KRW | 0.0% |
| 2012 Q4 | 2.65 Billion KRW | 65.21% |
| 2012 FY | 7.93 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 142.82 Billion KRW | 92.348% |
| InBody Co.,Ltd | 44.46 Billion KRW | 75.422% |
| Curexo Inc. | 1.13 Billion KRW | -862.571% |
| Seegene, Inc. | -30 Billion KRW | 136.421% |
| Ray Co., Ltd. | 6.11 Billion KRW | -78.633% |
| Gencurix Inc. | -12.37 Billion KRW | 188.312% |
| Sugentech Inc. | -22.74 Billion KRW | 148.058% |
| L&C Bio Co., Ltd | 6.66 Billion KRW | -63.937% |